Cargando…

CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis

BACKGROUND: Serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA) and CYFRA21-1 are the commonly used biomarkers to identify patients with autoimmune pulmonary alveolar proteinosis (APAP). However, it is not clear which of the biomarkers is more sensitive to the severity of the patient’s...

Descripción completa

Detalles Bibliográficos
Autores principales: Bai, Jiu-Wu, Gu, Shui-Yi, Sun, Xiao-Li, Lu, Hai-Wen, Liang, Shuo, Xu, Jin-Fu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725332/
https://www.ncbi.nlm.nih.gov/pubmed/34980056
http://dx.doi.org/10.1186/s12890-021-01795-x
_version_ 1784626093068648448
author Bai, Jiu-Wu
Gu, Shui-Yi
Sun, Xiao-Li
Lu, Hai-Wen
Liang, Shuo
Xu, Jin-Fu
author_facet Bai, Jiu-Wu
Gu, Shui-Yi
Sun, Xiao-Li
Lu, Hai-Wen
Liang, Shuo
Xu, Jin-Fu
author_sort Bai, Jiu-Wu
collection PubMed
description BACKGROUND: Serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA) and CYFRA21-1 are the commonly used biomarkers to identify patients with autoimmune pulmonary alveolar proteinosis (APAP). However, it is not clear which of the biomarkers is more sensitive to the severity of the patient’s condition. METHODS: APAP patients numbering 151 were enrolled in this study. All patients’ severity was assessed through the severity and prognosis score of PAP (SPSP). According to the respective laboratory upper limits of serum levels of LDH, CEA and CYFRA21-1, APAP patients were divided into higher and lower-level groups. Patients were divided into five groups based on SPSP. 88 patients had completed six months of follow-up. We calculated sensitivity, specificity, and critical point of LDH, CEA and CYFRA21-1 between APAP patients and normal control group, and between grade 1–2 and 3–5 through receiving operating characteristics (ROC) curve. RESULTS: Serum LDH, CEA and CYFRA21-1 levels of patients with PAP were higher and distinctly related to PaO(2), FVC, FEV(1), DLCO, HRCT scores and SPSP. The SPSP of patients in higher-level LDH, CEA and CYFRA21-1 groups were higher than those of corresponding lower-level groups. Based on SPSP results, the patients were divided into five groups (grade I, 20; grade II, 37; grade III, 40; grade IV, 38; grade V, 16). The serum level of CYFRA21-1 of patients with APAP in grade II was higher than that of patients in grade I and lower than that of patients in grade III. Serum CYFRA21-1 of patients with APAP after six months were higher than the baseline among the aggravated group. Serum LDH, CEA and CYFRA21-1 levels after six months among patients in the relieved group of patients with APAP were lower than the baseline. ROC correlating LDH, CEA and CYFRA21-1 values with APAP severity (between grade 1–2 and 3–5) showed an optimal cutoff of LDH of over 203 U/L (< 246 U/L), CEA of over 2.56 ug/L (< 10 ug/L), and CYFRA21-1 of over 5.57 ng/ml (> 3.3 ng/ml) (AUC: 0.815, 95% CI [0.748–0.882], sensitivity: 0.606, specificity: 0.877). CONCLUSION: Serum CYFRA21-1 level was more sensitive in revealing the severity of APAP than LDH and CEA levels among mild to moderate forms of disease.
format Online
Article
Text
id pubmed-8725332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-87253322022-01-06 CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis Bai, Jiu-Wu Gu, Shui-Yi Sun, Xiao-Li Lu, Hai-Wen Liang, Shuo Xu, Jin-Fu BMC Pulm Med Research BACKGROUND: Serum lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA) and CYFRA21-1 are the commonly used biomarkers to identify patients with autoimmune pulmonary alveolar proteinosis (APAP). However, it is not clear which of the biomarkers is more sensitive to the severity of the patient’s condition. METHODS: APAP patients numbering 151 were enrolled in this study. All patients’ severity was assessed through the severity and prognosis score of PAP (SPSP). According to the respective laboratory upper limits of serum levels of LDH, CEA and CYFRA21-1, APAP patients were divided into higher and lower-level groups. Patients were divided into five groups based on SPSP. 88 patients had completed six months of follow-up. We calculated sensitivity, specificity, and critical point of LDH, CEA and CYFRA21-1 between APAP patients and normal control group, and between grade 1–2 and 3–5 through receiving operating characteristics (ROC) curve. RESULTS: Serum LDH, CEA and CYFRA21-1 levels of patients with PAP were higher and distinctly related to PaO(2), FVC, FEV(1), DLCO, HRCT scores and SPSP. The SPSP of patients in higher-level LDH, CEA and CYFRA21-1 groups were higher than those of corresponding lower-level groups. Based on SPSP results, the patients were divided into five groups (grade I, 20; grade II, 37; grade III, 40; grade IV, 38; grade V, 16). The serum level of CYFRA21-1 of patients with APAP in grade II was higher than that of patients in grade I and lower than that of patients in grade III. Serum CYFRA21-1 of patients with APAP after six months were higher than the baseline among the aggravated group. Serum LDH, CEA and CYFRA21-1 levels after six months among patients in the relieved group of patients with APAP were lower than the baseline. ROC correlating LDH, CEA and CYFRA21-1 values with APAP severity (between grade 1–2 and 3–5) showed an optimal cutoff of LDH of over 203 U/L (< 246 U/L), CEA of over 2.56 ug/L (< 10 ug/L), and CYFRA21-1 of over 5.57 ng/ml (> 3.3 ng/ml) (AUC: 0.815, 95% CI [0.748–0.882], sensitivity: 0.606, specificity: 0.877). CONCLUSION: Serum CYFRA21-1 level was more sensitive in revealing the severity of APAP than LDH and CEA levels among mild to moderate forms of disease. BioMed Central 2022-01-03 /pmc/articles/PMC8725332/ /pubmed/34980056 http://dx.doi.org/10.1186/s12890-021-01795-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Bai, Jiu-Wu
Gu, Shui-Yi
Sun, Xiao-Li
Lu, Hai-Wen
Liang, Shuo
Xu, Jin-Fu
CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title_full CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title_fullStr CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title_full_unstemmed CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title_short CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
title_sort cyfra21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8725332/
https://www.ncbi.nlm.nih.gov/pubmed/34980056
http://dx.doi.org/10.1186/s12890-021-01795-x
work_keys_str_mv AT baijiuwu cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis
AT gushuiyi cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis
AT sunxiaoli cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis
AT luhaiwen cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis
AT liangshuo cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis
AT xujinfu cyfra211isamoresensitivebiomarkertoassesstheseverityofpulmonaryalveolarproteinosis